Beeline Medicines expanded its Series A fundraising by adding $126.3 million, bringing total disclosed capital to $426.3 million as it advances afimetoran for lupus and progresses other immunology programs. The company said the additional funding supports clinical and translational work ahead of data readouts tied to the lead small molecule. Beeline’s pipeline includes afimetoran in human testing and a biologic program, BLN-326, explored for diseases including atopic dermatitis and lupus. The company also outlined plans to start trials for additional programs, including a TYK2 inhibitor and an IL-18 receptor-targeting candidate, as it seeks to broaden its immune portfolio. Investors cited conviction in the opportunity for immune-mediated disease therapies, aligning with a wider biotech pattern of larger, venture-backed rounds aimed at de-risking clinical timelines. For sector participants, the enlarged round underscores continued capital focus on immunology assets with near-term human development milestones and pharma-like platform expansion plans.